Liquid-Powder Nasal Composition for Longer Mucosal Contact

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Nasal compositions in liquid form often flow out of the nasal cavity due to gravity and nasal clearance before being absorbed, reducing the efficacy of therapeutic agents.

Innovation Solution

A combination of a liquid and powder nasal composition, where the powder enhances the mucoadhesive properties of the liquid, prolonging its contact time with the nasal mucosa and increasing the absorption of therapeutic agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a liquid nasal composition is applied, then the therapeutic agent can be delivered to the nasal cavity, but the liquid flows out due to gravity and nasal clearance before absorption, reducing efficacy

Engineering Contradiction:
Improveefficacy of therapeutic agentVSAvoidcontact time with nasal mucosa
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention combines a liquid nasal composition containing therapeutic agents with a powder composition containing mucoadhesive polymers. When applied together, these materials form a composite formulation that adheres to the nasal mucosa, preventing premature clearance by gravity and nasal secretions. This composite approach allows the liquid therapeutic to remain in contact with the absorption site long enough to be effective.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The powder composition acts as an intermediary carrier that mediates between the liquid therapeutic agent and the nasal mucosa. The mucoadhesive polymer in the powder forms a matrix or gel that traps the liquid therapeutic and anchors it to the mucosal surface, serving as a bridge that prevents the liquid from flowing away while maintaining therapeutic contact.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If a mucoadhesive pharmaceutical solution is used, then the contact time and efficacy are improved, but the development cost and time increase due to fixed formulation requirements

Engineering Contradiction:
Improvecontact time and efficacyVSAvoiddevelopment cost and time
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The invention segments the nasal composition into two separate components: a liquid composition containing the therapeutic agent(s) and a powder composition containing the mucoadhesive polymer. This segmentation allows each component to be manufactured and formulated independently using existing, well-established formulations, avoiding the need to develop and approve a completely new fixed combination formulation while still achieving the benefits of mucoadhesion.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The powder composition containing mucoadhesive polymer serves multiple functions: it acts as an adhesive to retain the liquid therapeutic, provides a carrier matrix for drug delivery, and can potentially include additional therapeutic agents. This multi-functionality reduces the need for separate development of multiple components, simplifying the manufacturing and regulatory approval process.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The powder composition prolongs the liquid's contact time, enhancing the efficacy of therapeutic agents by increasing their absorption and maintaining their effects for a longer duration.

Implementation Method 1

the second powder composition part slowing down the clearance of the first liquid composition part due to the creation of weak and/or temporary bonds between one or more components of the first and second composition parts and/or between one or more components of the first and second composition parts and the nasal mucosa

Methodology Applied
Scientific EffectMucoadhesion: Adhesive

Implementation Method 2

A drug molecule can be transferred quickly from the nasal cavity across a single epithelial layer of the mucosa and directly into the systemic blood circulation of the patient

Methodology Applied
Scientific EffectAbsorption: Absorption (physical)

Data Source

PatentUS20250268866A1Nasal Compositions and Method of Use Thereof
Publication Date: 2025.08.28 KENVUE BRANDS LLC
  • US20250268866A1 patent drawing
  • US20250268866A1 patent drawing
  • US20250268866A1 patent drawing

AI summary

A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.